799 related articles for article (PubMed ID: 24081439)
61. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
[TBL] [Abstract][Full Text] [Related]
62. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
63. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
64. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
Calgüneri M; Pay S; Calişkaner Z; Apraş S; Kiraz S; Ertenli I; Cobankara V
Clin Exp Rheumatol; 1999; 17(6):699-704. PubMed ID: 10609068
[TBL] [Abstract][Full Text] [Related]
65. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
[TBL] [Abstract][Full Text] [Related]
66. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
[TBL] [Abstract][Full Text] [Related]
67. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S; Möttönen T; Hannonen P; Korpela M; Kautiainen H; Leirisalo-Repo M; Julkunen H; Luukkainen R; Hakala M; Vuori K; Laine AP; Toivanen A; Ilonen J;
Clin Exp Rheumatol; 2006; 24(6):636-42. PubMed ID: 17207378
[TBL] [Abstract][Full Text] [Related]
68. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
[TBL] [Abstract][Full Text] [Related]
69. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis.
Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G
J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758
[TBL] [Abstract][Full Text] [Related]
70. Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
Hua L; Du H; Ying M; Wu H; Fan J; Shi X
Medicine (Baltimore); 2020 Jul; 99(27):e20824. PubMed ID: 32629668
[TBL] [Abstract][Full Text] [Related]
71. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
O'Dell JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
[TBL] [Abstract][Full Text] [Related]
72. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
73. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
Kuusalo LA; Puolakka KT; Kautiainen H; Alasaarela EM; Hannonen PJ; Julkunen HA; Kaipiainen-Seppänen OA; Korpela MM; Möttönen TT; Paimela LH; Peltomaa RL; Yli-Kerttula TK; Leirisalo-Repo M; Rantalaiho VM;
Clin Exp Rheumatol; 2016; 34(6):1038-1044. PubMed ID: 27494516
[TBL] [Abstract][Full Text] [Related]
74. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
[TBL] [Abstract][Full Text] [Related]
75. Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial.
Nishiya K; Hisakawa N; Tahara K; Matsumori A; Ito H; Hashimoto K; Nakatani K; Takatori K
Acta Med Okayama; 1999 Dec; 53(6):275-9. PubMed ID: 10631383
[TBL] [Abstract][Full Text] [Related]
76. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
77. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
78. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.
Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y
Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
Mazouyès A; Clay M; Bernard AC; Gaudin P; Baillet A
Joint Bone Spine; 2017 Oct; 84(5):563-570. PubMed ID: 27989589
[TBL] [Abstract][Full Text] [Related]
80. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
